DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, racial disparity in mortality by state. CA Cancer J Clin 2017; 67: 439-48.
Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, et al. Risk factors of breast cancer: A systematic review and meta-analysis. Asia Pac J Public Health 2013; 25(5): 368-87.
Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve—an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 2002; 52: 595-638.
Cohen S, Janicki-Deverts D, Miller GE. Psychological stress and disease. JAMA 2007; 298: 1685-7.
Barik J, Marti F, Morel C, et al. Chronic stress triggers social aversion via glucocorticoid receptor in dopaminoceptive neurons. Science 2013; 339: 332-5.
Yuan A, Wang S, Li Z, Huang C. Psychological aspect of cancer from stressor to cancer progression. Exp Ther Med 2010; 11: 13-8.
Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 241: 125-32.
Mancino M, Ametller E, Gascón P, Almendro V. The neuronal influence on tumor progression. Biochim Biophys Acta 2011; 1816: 105-18.
Beaulieu J-M, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011; 63: 182-217.
Jafari M, Ahangari G, Saberi M, et al. Distorted expression of dopamine receptor genes in systemic lupus erythematosus. Immunobiology 2013; 218: 979-83.
Matthew T, Charlene S, Albert B. The effects of dopamine receptor 2 on breast cancer tumor initiating cells. [abstract]. Proceedings of the 107th Annual Meeting of the American Association for CancerResearch; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016; 76(14 Suppl): Abstract nr 3316.
Gholipour N, Ohradanova-Repic A, Ahangari G. A novel report of MiR‐4301 induces cell apoptosis by negatively regulating DRD2 expression in human breast cancer cells. J Cell Biochem 2018; 119(8): 6408-17.
Shaikhpoor MAGSM. Significant changes in D2-like dopamine gene receptors expression associated with Non- small -cell lung cancer: could it be of potential use in the design of future therapeutic strategies? Curr Cancer Ther Rev 2012; 8: 304-10.
Basu B, Sarkar C, Chakroborty D, et al. D1 and D2 dopamine receptor-mediated inhibition of activated normal T cell proliferation is lost in jurkat T leukemic cells. J Biol Chem 2010; 285: 27026-32.
Pornour M, Ahangari G, Hejazi S, Ahmadkhaniha H, Akbari M. Dopamine receptor gene (DRD1-DRD5) expression changes as stress factors associated with breast cancer. Asian Pac J Cancer Prev: APJCP 2014; 15: 10339.
Bhatia M, Sachlos E, Risueno RM. Treatment of cancer with dopamine receptor antagonists. EP2680853A1 2014.
Pijl H, Ohashi S, Matsuda M. A novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-61.
Kline CLB, Ralff MD, Lulla AR, et al. Role of Dopamine receptors in the anticancer activity of ONC201. Neoplasia 2018; 20(1): 80-91.
Li J, Yao QY, Xue JS, et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta Pharmacol Sin 2017; 38: 1282-96.
Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 2008; 14: 2502-10.
Minami K, Liu S, Liu Y, et al. Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis. Sci Rep 2017; 7: 45686.
Ghasem A, Majid P, Hossein B, et al. Significant association between Catechol Amine O-Methyl Transferase (COMT) gene expression changes and breast cancer pathogenesis. J Carcinog Mutagen 2015; 6: 2.
Hoeppner LH, Wang Y, Sharma A, et al. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol 2015; 9: 270-81.
Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001; 7: 569-74.
De Leeuw Van Weenen JPE, Maechler P, et al. The dopamine receptor D2 agonist Bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells. Biochem Pharmacol 2010; 79: 1827-36.
Rai S, Tanaka H, Suzuki M, et al. Chlorpromazine, an inhibitor of intracellular trafficking of FLT3-ITD and KIT D816V, shows prominent anti-leukemic activities against AML cells and AML stem cells in vitro and in vivo. Blood 2014; 124: 269.